DRR168611
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.590
- G2M_CHECKPOINT+0.540
- MYC_TARGETS_V1+0.370
- MYC_TARGETS_V2+0.340
- UNFOLDED_PROTEIN_RESPONSE+0.300
- MITOTIC_SPINDLE+0.290
- MTORC1_SIGNALING+0.290
- SPERMATOGENESIS+0.290
- PROTEIN_SECRETION+0.240
- ALLOGRAFT_REJECTION+0.200
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
- P53_PATHWAY-0.270
- FATTY_ACID_METABOLISM-0.260
- NOTCH_SIGNALING-0.250
- TGF_BETA_SIGNALING-0.230
- TNFA_SIGNALING_VIA_NFKB-0.230
- ADIPOGENESIS-0.220
- CHOLESTEROL_HOMEOSTASIS-0.220
- PEROXISOME-0.220
- APOPTOSIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A07C-01A-11R-A034-07 | — | E | 0.813 |
| 2 | SJEPD032407_D2.RNA-Seq | EPN | Anaplastic EPN | 0.803 |
| 3 | 7804d9f9-1252-4543-9a42-d53f371f35b6 | — | — | 0.790 |
| 4 | TCGA-OR-A5KZ-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.790 |
| 5 | SRR6013562 | — | cohortSQ2 | 0.787 |
| 6 | TCGA-85-6560-01A-11R-1820-07 | — | cohortMD1 | 0.775 |
| 7 | BS_MB7WN0ZB | Embryonal tumors | — | 0.764 |
| 8 | 63f6d3e9-3f4b-44fa-8e48-980c70b7e4f1 | — | — | 0.763 |
| 9 | TCGA-56-6546-01A-11R-1820-07 | — | cohortMD1 | 0.761 |
| 10 | 12a488c6-c319-4f40-9f62-82e74773370c | — | — | 0.757 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.090 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.080 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.070 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.030 | Remibrutinib | — uncovered |